REGN9933A2
-
Regeneron’s Factor XI Antibodies Show Antithrombotic Promise in Phase 2 Trials; Results Presented at AHA and Published in *The Lancet*
Regeneron (REGN) announced positive Phase 2 data for REGN7508Cat and REGN9933A2, two factor XI antibodies, in preventing postoperative venous thromboembolism (VTE) after total knee replacement. REGN7508Cat showed a 7.1% VTE rate, outperforming enoxaparin. REGN9933A2 had a 17.2% VTE rate. Importantly, no major bleeding events occurred. Phase 3 trials are underway. An investor roundtable is scheduled for November 10, 2025.
